135 related articles for article (PubMed ID: 2890665)
21. Comparison of the antihypertensive effects of betaxolol to atenolol.
Mroczek WJ; Burris JF; Hogan LB; Citron DC; Barker AH; McDonald RH
Am J Cardiol; 1988 Apr; 61(10):807-11. PubMed ID: 2895577
[TBL] [Abstract][Full Text] [Related]
22. Effect of carvedilol on ambulatory blood pressure, renal hemodynamics, and cardiac function in essential hypertension.
Dupont AG; Van der Niepen P; Taeymans Y; Ingels M; Piepsz A; Bossuyt AM; Block P; Six RO; Jonckheer MH; Vanhaelst L
J Cardiovasc Pharmacol; 1987; 10 Suppl 11():S130-6. PubMed ID: 2454359
[TBL] [Abstract][Full Text] [Related]
23. Letter: Beta receptors and renin release.
Amery A; Billiet L; Fagard R
N Engl J Med; 1974 Jan; 290(5):284. PubMed ID: 4148766
[No Abstract] [Full Text] [Related]
24. Long-term renal hemodynamic effects of nadolol in patients with essential hypertension.
Frohlich ED; Messerli FH; Deslinski GR; Kobrin I
Am Heart J; 1984 Oct; 108(4 Pt 2):1141-3. PubMed ID: 6148875
[TBL] [Abstract][Full Text] [Related]
25. [Acute combined alpha- and beta-adrenergic blockade in essential hypertension: effects on blood pressure, renal function, renin, and aldosterone].
Grüninger U; Akert R; Hunkeler H; Wegmüller E; Weidmann P; Hodler J
Klin Wochenschr; 1979 Jul; 57(14):731-9. PubMed ID: 470335
[TBL] [Abstract][Full Text] [Related]
26. Beta-adrenoceptor blocking effects and pharmacokinetics of betaxolol (SL 75212) in man.
Giudicelli JF; Chauvin M; Thuillez C; Richer C; Bianchetti G; Gomeni R; Morselli PL
Br J Clin Pharmacol; 1980 Jul; 10(1):41-9. PubMed ID: 6104973
[TBL] [Abstract][Full Text] [Related]
27. Acute and long-term studies of the mechanisms of action of beta-blocking drugs in lowering blood pressure.
Stumpe KO; Kolloch R; Vetter H; Gramann W; Krück F; Ressel C; Higuchi M
Am J Med; 1976 May; 60(6):853-65. PubMed ID: 14499
[TBL] [Abstract][Full Text] [Related]
28. [Antihypertensive effect of betaxolol, a cardioselective beta-adrenoceptor antagonist, in experimental hypertensive rats].
Bessho H; Suzuki J; Narimatsu A; Tobe A
Nihon Yakurigaku Zasshi; 1990 Jun; 95(6):347-54. PubMed ID: 1974238
[TBL] [Abstract][Full Text] [Related]
29. Antihypertensive activity of bucumolol, a beta-adrenergic blocking agent, in spontaneously hypertensive rats.
Miyamoto M; Koike H; Ito K; Nishino H
J Pharmacobiodyn; 1981 Jul; 4(7):455-60. PubMed ID: 6117610
[TBL] [Abstract][Full Text] [Related]
30. [Effect of betaxolol on atrial natriuretic peptide regulation in patients with essential hypertension].
Heering P; Hollenbeck M; Plum J; Grabensee B
Z Kardiol; 1990 Feb; 79(2):134-8. PubMed ID: 2138833
[TBL] [Abstract][Full Text] [Related]
31. Acute effects of prizidilol on blood pressure, heart rate, catecholamines, renin and aldosterone in essential hypertension.
Bianchetti MG; Boehringer K; Weidmann P; Link L; Schiffl H; Ziegler WH
Eur J Clin Pharmacol; 1982 Oct; 23(4):289-96. PubMed ID: 6129141
[TBL] [Abstract][Full Text] [Related]
32. β-Blocker withdrawal is preferable for accurate interpretation of the aldosterone-renin ratio in chronically treated hypertension.
Browne GA; Griffin TP; O'Shea PM; Dennedy MC
Clin Endocrinol (Oxf); 2016 Mar; 84(3):325-31. PubMed ID: 26300226
[TBL] [Abstract][Full Text] [Related]
33. Greater reductions in plasma aldosterone with aliskiren in hypertensive patients with higher soluble (Pro)renin receptor level.
Bokuda K; Morimoto S; Seki Y; Yatabe M; Watanabe D; Yatabe J; Ando T; Shimizu S; Itoh H; Ichihara A
Hypertens Res; 2018 Jun; 41(6):435-443. PubMed ID: 29618841
[TBL] [Abstract][Full Text] [Related]
34. Cardiovascular effects of befunolol, betaxolol and timolol eye drops.
Dorigo MT; Cerin O; Fracasso G; Altafini R
Int J Clin Pharmacol Res; 1990; 10(3):163-6. PubMed ID: 1977708
[TBL] [Abstract][Full Text] [Related]
35. Decreased intraocular pressure in the hypertensive human eye with betaxolol, a beta 1-adrenergic antagonist.
Feghali JG; Kaufman PL
Am J Ophthalmol; 1985 Dec; 100(6):777-82. PubMed ID: 2866715
[TBL] [Abstract][Full Text] [Related]
36. Beta-adrenergic receptor blockade as a therapeutic approach for suppressing the renin-angiotensin-aldosterone system in normotensive and hypertensive subjects.
Blumenfeld JD; Sealey JE; Mann SJ; Bragat A; Marion R; Pecker MS; Sotelo J; August P; Pickering TG; Laragh JH
Am J Hypertens; 1999 May; 12(5):451-9. PubMed ID: 10342782
[TBL] [Abstract][Full Text] [Related]
37. Antihypertensive effects of bunitrolol in essential hypertension.
Yoshimura M; Shikuma R; Takashina R; Takeda K; Takahashi H; Ijichi H; Kajita Y; Yamazaki H
Arzneimittelforschung; 1983; 33(8):1181-4. PubMed ID: 6139114
[No Abstract] [Full Text] [Related]
38. Acute effects of the calcium antagonist, nifedipine, on blood pressure, pulse rate, and the renin-angiotensin-aldosterone system in patients with essential hypertension.
Hiramatsu K; Yamagishi F; Kubota T; Yamada T
Am Heart J; 1982 Dec; 104(6):1346-50. PubMed ID: 6293295
[TBL] [Abstract][Full Text] [Related]
39. Humoral effects of long-term oral enalapril therapy.
Reams GP; Bauer JH
Am J Kidney Dis; 1986 May; 7(5):402-6. PubMed ID: 3010707
[TBL] [Abstract][Full Text] [Related]
40. Treatment with patiromer decreases aldosterone in patients with chronic kidney disease and hyperkalemia on renin-angiotensin system inhibitors.
Weir MR; Bakris GL; Gross C; Mayo MR; Garza D; Stasiv Y; Yuan J; Berman L; Williams GH
Kidney Int; 2016 Sep; 90(3):696-704. PubMed ID: 27350174
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
